Related Experiment Video

Updated: Aug 14, 2026

RNA Pull-down Procedure to Identify RNA Targets of a Long Non-coding RNA
09:36

RNA Pull-down Procedure to Identify RNA Targets of a Long Non-coding RNA

Published on: April 10, 2018

Identification of the biological affection of long noncoding RNA BC200 in Alzheimer's disease

Huanyin Li, Lan Zheng, Aihua Jiang

    Neuroreport
    |July 7, 2018
    PubMed

    Insights

    Blocking the long noncoding RNA BC200 with siRNA shows promise for Alzheimer's disease (AD) therapy. Inhibiting BC200 enhances cell viability and reduces apoptosis in AD models by targeting BACE1.

    Area of Science:

    • Molecular Biology
    • Neuroscience
    • Genetics

    Background:

    • Alzheimer's disease (AD) is a neurodegenerative disorder characterized by amyloid-beta (Aβ) peptide accumulation.
    • Long noncoding RNAs (lncRNAs) are increasingly implicated in disease pathogenesis, with BC200 found at high levels in AD.
    • Therapeutic strategies targeting lncRNAs like BC200 are under investigation for AD treatment.

    Purpose of the Study:

    • To investigate the role of BC200 in an Alzheimer's disease cell model.
    • To determine the effect of BC200 modulation on cell viability and apoptosis.
    • To elucidate the underlying molecular mechanisms, particularly the involvement of BACE1.

    Main Methods:

    • Establishment of an AD cell model overexpressing amyloid-beta (Aβ)1-42.
    • Modulation of BC200 levels using siRNA (knockdown) and mimics (overexpression).
    • Assessment of cell viability via MTT assay and apoptosis via flow cytometry.
    • Measurement of BACE1 expression levels.

    Main Results:

    • BC200 knockdown significantly suppressed BACE1 expression in the AD model.
    • BC200 overexpression led to increased BACE1 expression.
    • Inhibition of BC200 enhanced cell viability and reduced apoptosis in the AD model.
    • BC200 directly targets and regulates BACE1, influencing AD pathology.

    Conclusions:

    • BC200 plays a significant role in regulating cell viability and apoptosis in Alzheimer's disease.
    • Targeting BC200, potentially via BACE1, offers a novel therapeutic strategy for AD.
    • BC200 represents a potential therapeutic target for genetic interventions in Alzheimer's disease.

    More Related Videos

    Identification of Circular RNAs using RNA Sequencing08:25

    Identification of Circular RNAs using RNA Sequencing

    Published on: November 14, 2019

    Biomarker Identification for Gender Specificity of Alzheimer's Disease Based on the Glial Transcriptome Profiles04:22

    Biomarker Identification for Gender Specificity of Alzheimer's Disease Based on the Glial Transcriptome Profiles

    Published on: May 20, 2024

    Related Concept Videos

    lncRNA - Long Non-coding RNAs02:39

    lncRNA - Long Non-coding RNAs

    In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA (lncRNA)...
    Alzheimer's Disease: Overview01:26

    Alzheimer's Disease: Overview

    Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
    The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
    Alzheimer Disease l: Introduction01:29

    Alzheimer Disease l: Introduction

    Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
    Alzheimer Disease ll: Pathophysiology01:23

    Alzheimer Disease ll: Pathophysiology

    Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
    Dementia l: Introduction01:22

    Dementia l: Introduction

    Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...